Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing To Advance Its Innovative Precision Proteomics Platform And Clinical Oncology Pipeline
Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing To Advance Its Innovative Precision Proteomics Platform And Clinical Oncology Pipeline
11/11/21, 8:00 AM
Location
watertownMoney raised
$100 million
Round Type
series b
Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based medicine, today announced the successful completion of an oversubscribed $100 million Series B financing. The financing was co-led by Wellington Management Company and Surveyor Capital (a Citadel company), with key participation from RA Capital Management and Perceptive Advisors. Additional new investors in the financing included Sands Capital, HBM Healthcare Investments, Marshall Wace, HealthCor Management, BB Pureos Bioventures, Acorn Bioventures, and existing investors, including Alexandria Venture Investments and Chione Ltd. In connection with the financing, Derek DiRocco, Ph.D., partner at RA Capital Management, will join the company’s Board of Directors.
Company Info
Location
watertown, south dakota, united states
Additional Info
The AP3 platform enables the creation of drug-specific proprietary OncoSignature® companion diagnostics that can be used to identify patients most likely to benefit from Acrivon’s medicines. Through its highly specific patient selection, the company seeks to accelerate clinical development and increase the probability of successful treatment outcome for patients. Acrivon is also developing additional pipeline programs targeting critical nodes in DNA Damage Response (DDR) and cell cycle regulation.